The Year in Biotech and What to Watch in 2019

Episode Summary

Executive Summary: Adam Feuerstein and Daniel Levine review a contradictory 2018 for biotech: strong funding, IPOs, approvals, and science, but falling stock prices, weak M&A, and disappointing immunotherapy results. They highlight gene therapy pricing as a looming policy and reimbursement challenge, note bispecific antibodies as an emerging theme, and look ahead to a grim JPMorgan conference mood amid biotech weakness and rising drug-pricing scrutiny.

Main Topics: Biotech’s paradoxical 2018 performance (Priority: 5/5): The sector saw abundant capital, record IPO activity, and solid scientific progress, yet biotech equities fell sharply due to both macro market pressure and an earlier sector-specific downturn. IPO boom and Moderna’s valuation (Priority: 4/5): Moderna’s blockbuster IPO symbolized the year’s frothy fundraising environment, but the post-offering decline suggested investor fatigue and a likely pause in new biotech listings. M&A disappointment and capital allocation (Priority: 4/5): Tax reform was expected to spur acquisitions, but companies largely used cash for share buybacks instead of buying smaller biotechs, disappointing investors. Immunotherapy combinations underwhelmed (Priority: 4/5): 2018 failed to deliver the anticipated wave of successful immunotherapy combinations, with major data readouts proving lackluster and key trials failing. Gene therapy, SMA, and pricing challenges (Priority: 5/5): Advances in gene therapy, especially for spinal muscular atrophy, raised hopes and profound pricing questions, with potential one-time treatment costs in the millions. Emerging cancer modalities: bispecific antibodies (Priority: 3/5): At ASH, bispecific antibodies stood out as a notable developing story, potentially competing with CAR-T by offering easier manufacturing and lower cost. Drug pricing politics and JPMorgan outlook (Priority: 4/5): With Democrats controlling the House and pricing still a bipartisan issue, Feuerstein expects congressional scrutiny to intensify; JPMorgan is likely to open in a bearish mood.

Key Arguments: Biotech’s science and funding remained strong in 2018 even as public-market sentiment deteriorated, showing a disconnect between fundamentals and stock performance. The IPO market became overcrowded; many companies went public, but investor attention and returns were diluted, making the window likely to close in 2019. Tax savings did not trigger a wave of biotech acquisitions; instead, many companies prioritized share repurchases over M&A. The much-hyped immunotherapy-combination wave did not materialize in 2018, with major failures and no breakout winners. Gene therapies are transformative clinically but could be financially unsustainable without new reimbursement models, especially for ultra-expensive one-time treatments. Bispecific antibodies may become an important cancer-treatment platform because they could be simpler and cheaper to produce than CAR-T. Drug pricing will remain politically salient and may produce bipartisan legislative action or at least sustained congressional pressure. The biotech press landscape is changing, with stronger specialist outlets and paywall-supported journalism better positioned to cover complex healthcare stories.

Data Points: Biotech IPO market: Record numbers of IPOs - 2018 saw unusually heavy biotech public offerings, contributing to investor overload. Drug approvals: Record numbers of drug approvals - Feuerstein cited approvals as evidence that the science side of biotech kept moving forward. Novartis gene therapy price expectation: $2 million to $5 million per patient - Potential pricing range discussed for a coming gene-therapy product in spinal muscular atrophy. ASH thematic shift: Bispecific antibodies emerging as a major story - Feuerstein described bispecifics as a notable trend at the hematology meeting. M&A expectation vs. reality: Tax savings redirected to buybacks - Biopharma used capital for share repurchases rather than acquisitions. Cystic fibrosis coverage potential: Up to 90% of patients - Vertex’s triple-combination CF regimen could potentially address most cystic fibrosis patients.

Pivotal Quotes: "WTF, exclamation point, I think, is where we are." — Adam Feuerstein: His shorthand characterization of the biotech market’s sharp and confusing downturn in 2018. "They were all losers." — Adam Feuerstein: His blunt assessment of the much-anticipated immunotherapy-combination field in 2018. "It’s a big open question about how we kind of deal with that." — Adam Feuerstein: On the unresolved reimbursement challenge posed by expensive gene therapies and cell therapies.

Implications: Biotech enters 2019 with weaker sentiment, likely fewer IPOs, ongoing pricing scrutiny, and unresolved reimbursement issues for transformative therapies. Companies with strong execution and differentiated data may still stand out, but policy and market volatility will shape valuations.